CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma

Hepatocellular carcinoma is one of most common solid cancers worldwide. Sorafenib is indicated as a treatment for advanced hepatocellular carcinoma (HCC). However, the clinical efficacy of sorafenib has been severely compromised by the development of drug resistance, and the precise mechanisms of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shuai, Yao, Yao, Xu, Guolong, Zhou, Chao, Zhang, Yuan, Sun, Jie, Jiang, Runqiu, Shao, Qing, Chen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974417/
https://www.ncbi.nlm.nih.gov/pubmed/29844385
http://dx.doi.org/10.1038/s41419-018-0681-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974417/
https://www.ncbi.nlm.nih.gov/pubmed/29844385
http://dx.doi.org/10.1038/s41419-018-0681-z

Ejemplares similares